Investing in turnarounds is always a risky play, but sometimes the upside is so large that it's worthwhile. Besides, the market often overreacts to setbacks, and for those who can see the long-term potential where others don't, there's money to be made.

With that in mind, let's vet a pair of biopharma businesses that some people expect to bounce back this year. Even if they're too risky to be appealing for an investment today, you might find that they're worth a purchase down the road.

Image source: Getty Images.

Continue reading

Source Fool.com